BriaCell Presents Clinical Data at the 2020 San Antonio Breast Cancer Symposium®
December 09 2020 - 8:00AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT)
(OTCQB:BCTXF),
a clinical-stage
biotechnology company specializing in targeted immunotherapies for
advanced breast cancer, is pleased to announce the presentation
results of the clinical studies with its lead product candidate,
Bria-IMT™, summarized in a poster session held on December 9 – 11
during the 2020 San Antonio Breast Cancer Symposium® (SABCS).
The poster summarizes the clinical and
pathological data of the Bria-IMT™ monotherapy (i.e. the Bria-IMT™
regimen alone) study and Phase I/IIa clinical study of Bria-IMT™ in
combination with immune checkpoint inhibitors including
pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.),
and more recently, Incyte’s INCMGA00012 (by Incyte Corporation), in
advanced breast cancer.
Details and results on the poster presentation
are summarized below:
Abstract
Number: 1313Presentation
Title: Response to a modified whole tumor cell
targeted immunotherapy in patients with advanced breast cancer
correlates with tumor gradeSession
Date: December 9-11, 2020Program
Number: PS17-20Session
Title: Poster Session 17Summarized
Data: 30 patients were treated with the Bria-IMT™ regimen
(19 with the Bria-IMT™ regimen alone, 4 who began on the Bria-IMT™
regimen and transitioned to combination with a combination with
Incyte’s INCMGA00012, and 7 with combination therapy with of
Bria-IMT™ with KEYTRUDA®).
11 of those patients had moderately-well
differentiated tumors:
- 70% of these patients who were able
to develop an immune response showed disease control suggesting
that the Bria-IMT™, with a molecular signature most closely related
to moderately-well differentiated tumors, may result in disease
control especially in patients with moderately-well differentiated
tumors. These patients were very heavily pre-treated with a median
of 7 prior systemic therapy regimens (including chemotherapy,
biological and "targeted" therapy). The median Progression-free
survival (PFS) of this cohort was 5.7 months in the monotherapy
study, and 6.9 months in combination therapy. Of the group, there
were 9 patients with evaluable lesions including 6 with stable
disease and 2 with partial responses according to RECIST criteria.
One patient with stable disease had a marked reduction in numerous
non-target lesions. The data suggests clinical and survival benefit
for patients with moderately-well differentiated tumors who were
treated with the Bria-IMT™ regimen with or without check point
inhibitors. Notably, the survival benefit was higher in the group
that received the Bria-IMT™ regimen with check point inhibitors
suggesting an additive or synergistic effect.
- The median overall survival (OS)
for the combined monotherapy and combination therapy was 12.5
months (data on 6 patients with moderately-well differentiated
tumors). An OS of 7.2-9.8 months in similar patients with
metastatic breast cancer in the third line setting has recently
been published (Kazmi S, et al. “Overall survival analysis in
patients with metastatic breast cancer and liver or lung metastases
treated with eribulin, gemcitabine, or capecitabine.” Breast Cancer
Res Treat. 2020). This suggests a potentially significant survival
benefit for the patients treated with the Bria-IMT™ regimen alone
or in combination with check point inhibitors.
In summary, BriaCell
observed tumor reduction and clinical benefit in heavily
pre-treated advanced breast cancer patients, especially in those
with moderately-well differentiated tumors, treated with the
Bria-IMT™ regimen with or without immune checkpoint inhibitors. The
addition of immune checkpoint inhibitors to the Bria-IMT™ regimen
appeared to provide an additional clinical benefit suggesting an
additive or synergistic effect.
A copy of the poster will be posted at the
following: https://briacell.com/novel-technology/scientific-publications/.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024